Decreased need for RRT in liver transplant recipients after pretransplant treatment of hepatorenal syndrome-type 1 with terlipressin

What Was Tested

This randomized controlled trial paper looks at Terlipressin.

A post hoc analysis with a 12-month follow-up of LT recipients from a placebo-controlled trial of terlipressin (CONFIRM; NCT02770716) was conducted to evaluate the need for RRT and overall survival.

Why It Was Studied

Renal failure post-LT requiring renal replacement therapy (RRT) is a major risk factor for graft and patient survival.

RRT was defined as any type of procedure that replaced kidney function.

Who Took Part

The study group was 300 patients.

Patients with HRS-1 were treated with terlipressin plus albumin or placebo plus albumin for up to 14 days.

How the Study Was Run

The design is described as randomized and placebo-controlled.

The patients were allocated by chance, so the Terlipressin group and the comparison group should start out alike.

Some patients received a placebo instead of Terlipressin, giving a reference point.

The timeline in the abstract includes 14 days.

What Was Measured

Outcomes compared between groups included the incidence of HRS-1 reversal, the need for RRT (pretransplant and posttransplant), and overall survival.

PubMed files the paper under topics including Albumins, Hepatorenal Syndrome, Liver Cirrhosis, Liver Transplantation, Lypressin, Renal Replacement Therapy and Terlipressin.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Terlipressin in 300 patients over 14 days.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 2024 (Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society), a journal based in United States.

More context: the Terlipressin compound page, all human trials.